Holen Sie sich die Stockscreener-App
39.17
4.14%
-1.69
Handel nachbörslich:
39.17
Schlusskurs vom Vortag:
$40.86
Offen:
$39.84
24-Stunden-Volumen:
1.50M
Relative Volume:
0.93
Marktkapitalisierung:
$2.60B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-119.67M
KGV:
-14.35
EPS:
-2.73
Netto-Cashflow:
$-97.30M
1W Leistung:
-3.43%
1M Leistung:
+2.92%
6M Leistung:
+154.02%
1J Leistung:
+191.23%
1-Tages-Spanne:
$38.00
$42.00
1-Wochen-Bereich:
$38.00
$43.43
52-Wochen-Spanne:
$8.241
$44.80
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Firmenname
Mineralys Therapeutics Inc
Sektor
Branche
Telefon
(888) 378-6240
Adresse
150 N. RADNOR CHESTER ROAD, RADNOR
Vergleichen Sie MLYS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
39.17 | 3.17B | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-11 | Eingeleitet | Jefferies | Hold |
| 2024-07-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-02 | Eingeleitet | Goldman | Buy |
| 2023-03-07 | Eingeleitet | BofA Securities | Buy |
| 2023-03-07 | Eingeleitet | Credit Suisse | Outperform |
| 2023-03-07 | Eingeleitet | Evercore ISI | Outperform |
| 2023-03-07 | Eingeleitet | Guggenheim | Buy |
| 2023-03-07 | Eingeleitet | Stifel | Buy |
| 2023-03-07 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Mineralys Therapeutics Inc Aktie (MLYS) Neueste Nachrichten
Will Mineralys Therapeutics Inc. stock remain a Wall Street favoriteTrade Ideas & Verified Entry Point Detection - newser.com
Will Mineralys Therapeutics Inc. stock recover faster than marketFed Meeting & Growth Focused Stock Pick Reports - newser.com
Momentum divergence signals in Mineralys Therapeutics Inc. chartEarnings Risk Report & Expert Approved Trade Ideas - newser.com
What moving averages say about Mineralys Therapeutics Inc.Quarterly Market Review & Verified Entry Point Signals - newser.com
Mineralys Therapeutics (NASDAQ: MLYS) sets Q3 results call for 4:30 p.m. ET - Stock Titan
Price action breakdown for Mineralys Therapeutics Inc.Weekly Volume Report & Weekly Breakout Opportunity Watchlist - newser.com
Multi factor analysis applied to Mineralys Therapeutics Inc.July 2025 Summary & Real-Time Market Sentiment Reports - newser.com
How rising interest rates impact Mineralys Therapeutics Inc. stockQuarterly Growth Report & Low Drawdown Trading Strategies - newser.com
Can Mineralys Therapeutics Inc. hit a new high this monthForecast Cut & Low Drawdown Momentum Trade Ideas - newser.com
How Mineralys Therapeutics Inc. stock reacts to Fed rate cutsWeekly Profit Recap & Verified Momentum Watchlists - newser.com
Real time scanner hits for Mineralys Therapeutics Inc. explainedPortfolio Risk Report & Smart Swing Trading Alerts - newser.com
Heatmap analysis for Mineralys Therapeutics Inc. and competitorsWeekly Market Outlook & Weekly Market Pulse Updates - newser.com
Mineralys Therapeutics Inc. stock trendline breakdownJuly 2025 Patterns & Real-Time Volume Trigger Notifications - newser.com
Jennison Associates LLC Sells 743,711 Shares of Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Why Mineralys Therapeutics Inc. stock is favored by top institutionsWatch List & Real-Time Buy Signal Alerts - newser.com
Is Mineralys Therapeutics Inc. stock a dividend growth opportunity2025 Technical Patterns & High Accuracy Swing Entry Alerts - newser.com
Has Mineralys Therapeutics Inc. found a price floorQuarterly Earnings Summary & Short-Term High Return Strategies - newser.com
Mineralys Therapeutics (NASDAQ:MLYS) Price Target Raised to $52.00 - MarketBeat
Analysts Conflicted on These Healthcare Names: Bausch Health Companies (BHC), Thermo Fisher (TMO) and Mineralys Therapeutics, Inc. (MLYS) - The Globe and Mail
Will Mineralys Therapeutics Inc. stock maintain growth storyBuy Signal & Community Verified Trade Alerts - newser.com
Mineralys Therapeutics to Present Key Lorundrostat Data at ASN Kidney Week 2025 - MSN
Is Mineralys Therapeutics Inc a good long term investmentMarket Breadth Indicators & Free High Velocity Capital Growth - earlytimes.in
Ranking Mineralys Therapeutics Inc. among high performing stocks via toolsMarket Trend Review & Verified Technical Signals - newser.com
Can machine learning forecast Mineralys Therapeutics Inc. recoveryQuarterly Trade Review & Capital Efficient Trade Techniques - newser.com
Mineralys Therapeutics prices upsized $250M stock offering - MSN
Why Mineralys Therapeutics Stock is Climbing Higher - TipRanks
Mineralys Therapeutics price target raised to $52 from $42 at H.C. Wainwright - TipRanks
HC Wainwright & Co. Maintains Mineralys Therapeutics (MLYS) Buy Recommendation - Nasdaq
Is Mineralys Therapeutics Inc. stock recession proofJuly 2025 Opening Moves & Real-Time Market Sentiment Alerts - newser.com
Finanzdaten der Mineralys Therapeutics Inc-Aktie (MLYS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):